4.000EUR+0.13%Mkt Cap: 1.03B $P/E: —Today
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap1.03B $
Enterprise Value1.04B $
Revenue (TTM)7.35M $
Gross Profit7.33M $
Net Income (TTM)-384.93M $
Revenue/Share0.0391 USD
Last Price4.000 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees69
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012
Valuation
P/E (Trailing)—
P/E (Forward)-4.87
PEG—
EV/EBITDA-7.19
EV/Revenue140.89
P/S138.18
P/B-26.72
EPS (TTM)-1.90
EPS (Forward)-0.81
52W Range
2.88034% of range6.200
52W High6.200 EUR
52W Low2.880 EUR
Profitability
Gross Margin99.68%
Oper. Margin-6710.69%
EBITDA Margin0.00%
Profit Margin-7899.58%
ROE1241.63%
ROA-141.93%
Growth
Revenue Growth-89.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-114.00M $
CapEx (TTM)268.48K $
FCF Margin-2968.67%
FCF Yield-21.14%
Net Debt142.45M $
Net Debt/EBITDA-0.99
Balance Sheet
Debt/Equity-2.10
Current Ratio3.16
Quick Ratio1.41
Book Value/Sh-0.1480 EUR
Cash/Share0.4810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.634 EUR
Upside (mean)+140.9%
Target Range7.000 EUR – 15.37 EUR
€7.000+140.9% to mean€15.37
# Analysts5
Ownership
Shares Out.236.22M
Float157.92M
Insiders12.67%
Institutions49.72%
Technical
SMA 503.636 (+10.0%)
SMA 2004.310 (-7.2%)
Beta0.91
S&P 52W Chg18.16%
Avg Vol (30d)251.32K
Avg Vol (10d)253.99K
Technical Indicators
RSI (14)53.3
MACD0.0703
MACD Signal0.0855
MACD Hist.-0.0152
BB Upper4.216 EUR
BB Middle3.967 EUR
BB Lower3.717 EUR
BB Width12.58%
ATR (14)0.2125 EUR
Vol Ratio (20d)0.81x